Feb 10, 2026 04:05PM
Feb 4, 2026 07:08AM
Feb 2, 2026 08:03AM
Feb 2, 2026 08:00AM
Jan 12, 2026 04:05AM
Jan 11, 2026 04:00PM
Dec 12, 2025 10:31AM GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Nov 4, 2025 04:05PM
Oct 21, 2025 07:00AM
Oct 18, 2025 03:00AM
Oct 18, 2025 03:00AM
Jul 28, 2025 04:05PM
Jul 24, 2025 05:04PM
Jul 24, 2025 05:04PM Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
Jul 24, 2025 04:31AM
Jun 20, 2025 06:54AM
May 13, 2025 04:07PM
Apr 12, 2025 04:00AM
Mar 27, 2025 06:37AM
Mar 26, 2025 01:08PM
Mar 26, 2025 01:07PM Exelixis (EXEL) PT Raised to $33 at Leerink Partners
Mar 26, 2025 10:56AM
Mar 26, 2025 09:15AM
Mar 26, 2025 09:15AM
Mar 25, 2025 05:15PM
Feb 15, 2025 11:10AM
Feb 11, 2025 04:05PM
Jan 24, 2025 02:31PM Exelixis (EXEL) Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study
Jan 24, 2025 02:30PM
Jan 15, 2025 05:11PM
Jan 13, 2025 12:50PM
Jan 12, 2025 04:00PM
Jan 9, 2025 09:00AM
Dec 19, 2024 11:16AM
Dec 17, 2024 08:00AM Sairopa reports research milestones achieved in partnership with Exelixis, totalling $35 Million from consecutive clinical milestone payments in 2024
Nov 27, 2024 07:08AM
Nov 26, 2024 04:05PM
Oct 29, 2024 04:05PM
Oct 15, 2024 01:57PM
Oct 15, 2024 01:57PM
Oct 14, 2024 08:02AM
Oct 14, 2024 08:00AM Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELI
Sep 16, 2024 02:01PM
Sep 16, 2024 08:45AM
Sep 16, 2024 08:45AM
Sep 15, 2024 08:45AM
Aug 6, 2024 04:05PM
Aug 6, 2024 08:30AM
Aug 6, 2024 08:30AM Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
May 20, 2024 01:52PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All